. 2022 Apr;11(4):669–677. doi: 10.21037/tcr-21-2334

Table 3. Prognostic factors of enrolled 248 HCC patients.

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95% CI	P	HR	95% CI	P
Age (years)
<60	1	0.484–1.749	0.800	–	–	–
≥60	0.921	0.484–1.749	0.800	–	–	–
Sex
Male	1	0.786–1.643	0.497	–	–	–
Female	1.136	0.786–1.643	0.497	–	–	–
HBV
Negative	1	1.281–8.299	0.013	1	1.349–9.064	0.010
Positive	3.260	1.281–8.299	0.013	3.496	1.349–9.064	0.010
HCV
Negative	1	0.139–2.394	0.449	–	–	–
Positive	0.578	0.139–2.394	0.449	–	–	–
Tumor number
Single	1	0.375–3.942	0.745	–	–	–
Multiple	1.215	0.375–3.942	0.745	–	–	–
Tumor size (cm)
<5	1	1.188–4.006	0.012	1	1.372–4.992	0.003
≥5	2.182	1.188–4.006	0.012	2.617	1.372–4.992	0.003
BCLC stage
0	1	–	–	–	–	–
A	1.840	0.550–6.157	0.323	–	–	–
B	2.938	0.861–10.032	0.085	–	–	–
Histological grade
I	1	–	–	1	–	–
II	8.302	1.130–60.963	0.037	5.604	0.749–41.955	0.093
III	6.030	0.777–46.790	0.086	3.165	0.397–25.223	0.277
Tissue AFP status (IHC)
Negative	1	1.299–4.361	0.005	1	0.892–4.576	0.092
Positive	2.380	1.299–4.361	0.005	2.020	0.892–4.576	0.092
Serum AFP (ng/mL)
<92.33	1	1.129–3.796	0.019	1	0.426–2.235	0.955
≥92.33	2.070	1.129–3.796	0.019	0.976	0.426–2.235	0.955

HCC, hepatobiliary carcinoma; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona clinic liver cancer; AFP, alpha-fetoprotein; IHC, immunohistochemistry.